Novartis update on delpacibart etedesiran Phase III HARBOR study
Novartis provided an update on its Phase III HARBOR study of delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1 (DM1).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.